Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;31(2):316-328.
doi: 10.1002/oby.23639.

Obesity among Asian American people in the United States: A review

Affiliations
Review

Obesity among Asian American people in the United States: A review

Zhaoping Li et al. Obesity (Silver Spring). 2023 Feb.

Abstract

Standard measures of obesity, i.e., body weight and BMI, suggest that Asian American people have a lower obesity prevalence than other racial groups in the United States. However, Asian American people face a unique challenge in their pattern of adiposity with central obesity, which raises the risk for multiple comorbidities, such as type 2 diabetes, metabolic syndrome, and cardiovascular disease, at a lower BMI compared with other populations. Several organizations recommend lower BMI cutoffs for obesity in Asian people (BMI ≥25.0 or ≥27.5 kg/m2 ) instead of the standard ≥30.0 kg/m2 threshold. The risks of obesity and related comorbidities in this population are further influenced by diet, physical activity, perceptions of health, and access to information and therapies. Asian-specific parameters for assessing obesity should become a standard part of clinical practice. Asian American people should equally be offered subgroup-specific tailored interventions owing to heterogeneity of this population. Access to medications and surgery should be improved, in part by updating US indications for therapies to reflect race-specific obesity thresholds and through inclusion of Asian American people of all subtypes with lower BMI values in clinical trials.

PubMed Disclaimer

Conflict of interest statement

Zhaoping Li and Sunil Daniel declared no conflict of interest. Ken Fujioka reports consultancy fees from Amgen Inc.; Boehringer Ingelheim; Gelesis; Janssen Global Services, LLC; Nalpropion Pharmaceuticals, Inc.; Novo Nordisk; and Rhythm Pharmaceuticals, Inc. Devika Umashanker reports consultancy fees from Novo Nordisk.

Similar articles

Cited by

References

    1. Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an Endocrine Society scientific statement. Endocr Rev. 2018;39:79‐132. - PMC - PubMed
    1. WHO Expert Consultation . Appropriate body‐mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157‐163. - PubMed
    1. Misra A, Chowbey P, Makkar BM, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163‐170. - PubMed
    1. Kohda Y. Paradigm change to future health enhancement through comprehending the concept of obesity disease in Japan. J Clin Toxicol. 2018;8:1000389. doi:10.4172/2161-0495.1000389. - DOI
    1. Seo MH, Lee WY, Kim SS, et al. 2018 Korean Society for the Study of Obesity guideline for the management of obesity in Korea. J Obes Metab Syndr. 2019;28:40‐45. - PMC - PubMed

Publication types